Sarepta Therapeutics Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (47)

Latest Posts

About This Stock More About This Stock
Sarepta Price Target Raised To $168 From $83 At Piper Jaffray
Article By: The Fly
Wednesday, June 20, 2018 7:15 AM EDT
Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics to $168 from $83 after the company presented Phase I/II data on three Duchenne muscular dystrophy boys receiving its micro-dystrophin gene therapy.
In this article: SRPT
Read
Biotech Stocks Emerge Unscathed And Ready To Go
Article By: Tarun Chandra, CFA
Friday, May 18, 2018 8:41 PM EDT
The biotech stocks have been demonstrating strong resilience in the face of intense volatility since February and, remarkably, keeping pace with the broader indexes, considering the highly speculative and volatile nature of the group.
In this article: CVS, MRK, IBB, INCY, ESRX, XBI, ARNA, ECYT, IMMU, IRWD, DVAX, SUPN, SRPT, AGIO, QURE, HRTX, LOXO, ATRA, BGNE, ADAP, CRSP, CBIO, GTHX, MRTX
Read
Sarepta Drops After U.K. Trial Halt, But Analysts Unconcerned
Article By: The Fly
Friday, February 9, 2018 1:50 PM EDT
Shares of Sarepta Therapeutics dropped in morning trading following a report that said that the company had halted treatment at sites in the United Kingdom testing its Duchenne muscular dystrophy drug golodirsen.
In this article: SRPT Also: SLDB
Read
E Why Sarepta Therapeutics Inc Looks On Track For A Second DMD Approval
Article By: Samuel Rae
Wednesday, October 11, 2017 9:36 AM EDT
Here's a look at Sarepta's latest data and where it fits into the company's Duchenne muscular dystrophy (DMD) portfolio. From a trader's perspective, Sarepta looks like it could be a strong pick heading into early 2018 and beyond.
In this article: SRPT
Read
Top Analysts Are Betting On These 5 Hot Stocks For 2018
Article By: TipRanks
Sunday, October 8, 2017 3:36 PM EDT
Biopharma Sarepta Therapeutics is soaring right now, and top analysts are confident that this stock still has further room to grow. Analysts are predicting that Sarepta can climb by a further 29% over the next 12 months.
In this article: GVA, FOLD, AVGO, SRPT, JD
Read

PARTNER HEADLINES

Latest Tweets for $SRPT

No tweets yet!

$SRPT

Why Sarepta Therapeutics Inc Looks On Track For A Second DMD Approval
Carol Klein 10/11/2017 1:39:12 PM

Looks promising, thanks. $SRPT.

1 to 1 of 1 comments